Previous 10 | Next 10 |
2023-12-08 08:34:55 ET Summary Exscientia is a pharmaceutical company using AI-based precision engineering to revolutionize drug discovery and reduce drug creation by 70%. The company has strong financials, with a cash runway into 2026 and partnerships with industry giants such as...
2023-12-07 08:15:00 ET What's more cool than a biotech company developing cutting-edge cures for intractable maladies? A biotech company developing cutting-edge cures using artificial intelligence (AI), of course. Exscientia (NASDAQ: EXAI) is one such business undertaking this effor...
$2.3 million grant expected to drive research to harness the host interferon response as a pathway to treating and preventing pandemic influenza Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder wi...
2023-11-21 09:27:03 ET More on Nvidia, Roche, etc. Nvidia Q3 Earnings Preview: Know The Risks And The Reward Nvidia: Smooth Sailing Nvidia Fiscal Q3 Earnings Preview: Big Wave Surfing 4 stocks to watch on Tuesday: Nvidia, Abercrombie & Fitch and more ...
Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6 th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT). A live webcast of the fireside chat will be availa...
2023-11-14 00:06:35 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks . Fundamentally, the reasoning centers on relative insulation...
2023-11-09 15:27:09 ET Exscientia plc (EXAI) Q3 2023 Results Conference Call November 09, 2023 08:30 AM ET Company Participants Sara Sherman - VP, IR Andrew Hopkins - CEO Dave Hallett - Chief Scientific Officer Ben Taylor - CFO and Chief Strategy Officer ...
Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below. Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST....
2023-11-09 06:08:18 ET More on Exscientia Exscientia: Merck Deal Further Cements Industry Positioning, Reiterate Buy Exscientia climbs as Merck KGaA joins AI drug discovery Seeking Alpha’s Quant Rating on Exscientia Historical earnings data for Exscien...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...